- Home
- NYT vs LEGN Comparison
NYT vs LEGN Comparison
Compare NYT & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYT
- LEGN
- Stock Information
- Founded
- NYT 1851
- LEGN 2014
- Country
- NYT United States
- LEGN United States
- Employees
- NYT N/A
- LEGN N/A
- Industry
- NYT Newspapers/Magazines
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- NYT Consumer Discretionary
- LEGN Health Care
- Exchange
- NYT Nasdaq
- LEGN Nasdaq
- Market Cap
- NYT 8.0B
- LEGN 7.0B
- IPO Year
- NYT N/A
- LEGN 2020
- Fundamental
- Price
- NYT $47.17
- LEGN $31.13
- Analyst Decision
- NYT Buy
- LEGN Strong Buy
- Analyst Count
- NYT 5
- LEGN 12
- Target Price
- NYT $56.00
- LEGN $79.00
- AVG Volume (30 Days)
- NYT 1.7M
- LEGN 1.2M
- Earning Date
- NYT 05-07-2025
- LEGN 03-11-2025
- Dividend Yield
- NYT 1.47%
- LEGN N/A
- EPS Growth
- NYT 26.43
- LEGN N/A
- EPS
- NYT 1.77
- LEGN N/A
- Revenue
- NYT $2,558,919,000.00
- LEGN $627,241,000.00
- Revenue This Year
- NYT $8.41
- LEGN $66.76
- Revenue Next Year
- NYT $5.95
- LEGN $51.82
- P/E Ratio
- NYT $27.73
- LEGN N/A
- Revenue Growth
- NYT 6.66
- LEGN 119.97
- 52 Week Low
- NYT $41.55
- LEGN $30.17
- 52 Week High
- NYT $58.16
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- NYT 39.99
- LEGN 36.80
- Support Level
- NYT $48.71
- LEGN $31.17
- Resistance Level
- NYT $50.35
- LEGN $34.84
- Average True Range (ATR)
- NYT 0.77
- LEGN 1.42
- MACD
- NYT 0.02
- LEGN -0.48
- Stochastic Oscillator
- NYT 13.46
- LEGN 11.16
About NYT New York Times Company (The)
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as NYTimes and various smartphone applications. The company has two segments: New York Times Group and The Athletic. The company generates the majority of its revenue from the NYTG segment. The NYTG and The Athletic segments derive revenue from subscriptions, Advertising, and others, where the majority source of revenue for both segments is subscription.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.